Physician profile
Ricardo E Rodriguez
NPI 1467471821
$5,447.44
in general payments reported to CMS, 2019-2025
31 companies · $1,052 in 2025
The $1,052 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $948 · 2020: $410 · 2021: $828 · 2022: $653 · 2023: $660 · 2024: $896 · 2025: $1,052.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,609.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,608.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,435.10 | 2019-2025 | Skyrizi, Rinvoq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $785.07 | 2019-2025 | Xifaxan, Trulance |
| Ironwood Pharmaceuticals, INC | $359.84 | 2019-2025 | Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $330.84 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $234.81 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Qol Medical, LLC | $213.55 | 2022-2025 | Sucraid, Sucraid |
| Vivus LLC | $189.42 | 2019-2025 | Qsymia, Pancreaze |
| Redhill Biopharma INC. | $176.94 | 2020-2025 | Talicia |
| Madrigal Pharmaceuticals | $166.17 | 2025 | Rezdiffra |
| Pfizer INC. | $163.28 | 2019-2025 | |
| Braintree Laboratories, INC. | $157.14 | 2019-2025 | Suflave, Sutab |
| Lilly USA, LLC | $140.64 | 2023-2025 | Omvoh, Zepbound, Mounjaro |
| Allergan, INC. | $139.48 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $125.10 | 2021-2024 | Dificid |
| Celgene Corporation | $84.72 | 2021-2023 | Zeposia |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $79.92 | 2022-2024 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $72.52 | 2020-2022 | |
| Celltrion USA INC. | $71.41 | 2025 | Vegzelma |
| Intercept Pharmaceuticals, INC. | $70.02 | 2019-2025 | Ocaliva |
| Exact Sciences Corporation | $64.90 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Cumberland Pharmaceuticals, INC. | $62.42 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.53 | 2020 | |
| Phathom Pharmaceuticals, INC. | $48.06 | 2024-2025 | Voquezna |
| Medtronic, INC. | $40.62 | 2022 | |
| Novo Nordisk INC | $38.08 | 2025 | Wegovy |
| Aimmune Therapeutics, INC. | $30.56 | 2025 | Zenpep |
| Concordia Pharmaceuticals INC. | $30.00 | 2019 | |
| Shionogi INC | $27.29 | 2019 | |
| Genzyme Corporation | $19.05 | 2023 | |
| Ferring Pharmaceuticals INC. | $16.77 | 2024 | Rebyota |
| Capsovision, INC. | $15.19 | 2025 | Capsocam Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ricardo Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.